SEARCH
Toggle navigation
Home
Services
Antibody Modification and Conjugation Technologies
Cysteine Conjugation
Carbohydrate Conjugation
Lysine Conjugation
Other Conjugation Approaches
Unnatural Amino Acids Conjugation
ADC Payloads Development
Biological Payloads
Chemical Payloads
ADC Analysis and Characterization
Bioanalytics
Bioassays
ADC Linkers Development
ADC Manufacture
ADC Linker and Cytotoxin Conjugations
Products
ADCs Cytotoxin
ADCs Cytotoxin with Linkers
ADCs Linker
Inquiry
Contact Us
About Us
Resource
News
Scientific Corner
News
Home
Resource
News
News
Cytotoxic payloads in ADCs
Disitamab Vedotin for the treatment of urothelial cancer was approved by the US FDA
Exatecan mesylate: a novel topoisomerase I inhibitor in ADC technolog
New medicine for lymphoma! Antibody-Drug Conjugate (ADC) loncastuximab tesirine (Lonca) applies for listing!
TF-targeted antibody-drug conjugate (ADC) tisotumab vedotin shows strong efficacy and will be applied marketing
The development history of ADC drugs
What is antibody drug conjugates?
What is Calicheamicin？
What is Monomethyl Auristatin E (MMAE)?
What is Monomethyl Auristatin F (MMAF)?
What is Pyrrolobenzodiazepine (PBD)?
*
Only for research. Not suitable for any diagnostic or therapeutic use.
Inquiry Basket
Loading ......
Delete selected
Go to checkout
